Dengue, Zika Drive Global Markets for Neglected Tropical Diseases

Written by Laurie L. Sullivan on Aug 31, 2017 10:00:00 AM

Vaccine.jpgThere is a growing need for the treatment or prevention of tropical diseases. Neglected tropical diseases are a significant cause of death and morbidity among affected communities worldwide. According to BCC Research, the total global addressable market for these diseases (see Table) was $1.4 billion in 2015. This market is projected to grow at a compound annual growth rate (CAGR) of 14.1% to surpass $2.6 billion by 2021. BCC Research’s study, Global Markets for Neglected Tropical Disease Treatments, found that some indications (such as the Ebola and Zika viruses) are resulting in double-digit sales growth, whereas others face declining investment.

Read More

Topics: Life Sciences, Pharmaceuticals

Chinese Startups Target Urgent Need for Cancer Screening and Treatment

Written by Laurie L. Sullivan on Aug 16, 2017 10:00:00 AM

Cancer Screening and Medical Treatment.jpgThe Chinese cancer intervention market is large, rapidly growing, and dominated by drug and equipment suppliers from outside of China. These are all important considerations for pharmaceutical companies in North America, Europe, and other developed regions that are seeking strong growth and high profits, reports BCC Research in a recent study, The Chinese Market for Cancer Intervention.

Read More

Topics: Life Sciences, Pharmaceuticals

See This, Hear This: Business Is Booming for Over-the-Counter Products

Written by Laurie L. Sullivan on Jul 31, 2017 11:00:00 AM

At the Internet of Things World 2017 conference held this month, self-healthcare emerged as one of the top 10 key areas that will drive growth in the Internet of Things. Self-healthcare was ranked with the likes of agriculture 2.0, smart cars, and energy grids. The use of over-the-counter (OTC) medications for self-treatment is on the rise. Major contributing factors include marketing of drugs in mass media, lack of time in people’s busy lives for appointments, and rising costs of health insurance. The National Library of Medicine states on its Web site that, although considered safe, there are risks associated with taking OTC medicines. Nonetheless, the market for these products is booming.

Read More

Topics: Life Sciences, Pharmaceuticals

Monetizing the Clinical Value of Breakthrough Therapies

Written by Laurie L. Sullivan on Jul 10, 2017 11:00:00 AM

The global market for drugs that fall under the Breakthrough Therapy Designation (BTD) is forecast to grow from $48.8 billion in 2017 to $99.2 billion by 2022, according to a comprehensive market analysis by BCC Research. In 2012, the US FDA launched the BTD pathway to expedite the approval of drug candidates that are intended to treat serious or life-threatening diseases and that outperform existing therapies. The European Medicines Agency introduced a similar fast-track program, called PRIME (PRIority MEdicines), in March 2016.

“Our analysis of the breakthrough drug market shows that companies have an opportunity to leapfrog the lengthy drug approval process by up to three years, generating hundreds of millions of dollars in revenue and maximizing the length of time their drug is on the market before their patent expires,” says Kevin Fitzgerald, BCC Research Editorial Director.

OPPORTUNITY AND CHALLENGES OF A BREAKTHROUGH STATUS

Read More

Topics: Life Sciences, Pharmaceuticals

Shedding Some Light on Harnessing the Immune System to Fight Cancer

Written by Laurie L. Sullivan on May 19, 2017 8:44:25 AM

With a stream of product approvals in recent years, the global immunotherapy market has hit its stride. In particular, immunotherapy for cancer is a hot area of research. According to BCC Research, the global cancer immunotherapy market should reach $96.5 billion in 2021, up from $73.0 billion in 2016, reflecting a compound annual growth rate (CAGR) of 5.7%. A surge in the use of checkpoint inhibitors, immunomodulatory therapies, and the development of next-generation oncolytic virotherapies are driving this growth.

Read More

Topics: Life Sciences, Pharmaceuticals

Fight the Resistance: New Therapies Needed for Prostate Cancer

Written by Laurie L. Sullivan on May 19, 2017 8:39:44 AM

BCC Research reports that an expanding population of patients with prostate cancer, the increasing demand for treatment, and emerging technologies are contributing to growth of the global prostate cancer market. Valued at $47.2 billion in 2016, this market is estimated to reach $65.1 billion by 2021 at a compound annual growth rate of 6.6%.

Read More

Topics: Life Sciences, Pharmaceuticals

Wanted: Novel Agents to Trounce Multidrug-Resistant Fungi

Written by Laurie L. Sullivan on May 9, 2017 7:51:49 PM

The battle cry against multidrug-resistant bacteria is loud and clear. Voices calling for novel antifungal agents are also rising, as fungi bolster the ranks of microbial infectious agents that are becoming increasingly drug resistant. Fungal infections are on the rise, many with lethal consequences. New proprietary research by BCC Research predicts that innovative antifungal drugs in development, along with a growing number of people with weakened immune systems and FDA fast-track provisions, are aiding growth in the global market for antifungal drugs. BCC Research expects the global market for antifungal drugs to reach $16.1 billion in 2021, up from $13.1 billion in 2016.

Read More

Topics: Life Sciences, Pharmaceuticals

Timely Data Sharing Is Key Part of Armamentarium for Influenza Control

Written by Laurie L. Sullivan on May 1, 2017 11:00:00 AM

 

Read More

Topics: Life Sciences, Pharmaceuticals

Infectious Diseases May Fuel China to Become Biggest Consumer of Drugs

Written by Laurie L. Sullivan on Apr 12, 2017 10:00:00 AM

China is one of the world’s largest and  Infectious Disease Drugs.jpgfastest-growing drug markets. At a five-year compound annual growth rate (CAGR) of 14.0%, BCC Research predicts that the Chinese drug market will reach $424.3 billion by 2021. At this pace, China is likely to overtake the United States to become the world’s largest consumer of drugs by 2025.

Read More

Topics: Life Sciences, Pharmaceuticals

Asia-Pacific, Kidney Disease Spur Erythropoietin Biosimilars Market

Written by Laurie L. Sullivan on Mar 28, 2017 10:30:00 AM

The global erythropoietin biosimilars market has been expanding rapidly in the past decade. This acceleration has primarily been the result of patent expiries of major erythropoietin biologics in the European market coupled with a demand for cheaper erythropoietin agents in the Asia-Pacific, South American, Middle Eastern, and African markets. BCC Research projects that over the next five years, the global market for erythropoietin biosimilars will continue to enjoy healthy gains while the global market for erythropoietin biologics (i.e., patented products) will shrink substantially.

Read More

Topics: Life Sciences, Pharmaceuticals

Popular Posts